cyclic
guanosin
monophosphateeadenosin
monophosph
synthas
cga
stimul
interferon
gene
sting
signal
pathway
play
critic
role
immun
respons
dna
pharmacolog
modul
sting
pathway
well
character
structur
function
perspect
pave
way
drug
design
small
modul
medicin
chemist
outlin
recent
progress
studi
sting
pathway
structur
biolog
function
sting
sting
relat
diseas
well
rational
progress
develop
sting
modul
review
demonstr
sting
promis
drug
target
provid
clue
discoveri
novel
sting
agonist
antagonist
potenti
treatment
variou
diseas
includ
microbi
infecti
diseas
cancer
autoimmun
diseas
finit
set
receptor
recogn
enorm
divers
potenti
pathogen
one
clear
except
gener
recognit
dnadth
basic
build
block
life
past
year
accumul
evid
indic
one
major
pathway
mediat
immun
respons
dna
govern
cgasst
signal
pathway
importantli
pathway
blind
dna
sequenc
univers
sens
mechan
break
one
fundament
rule
classic
pattern
recognit
dogma
appli
pathogenspecif
structur
pattern
selfnonself
discrimin
studi
identifi
sting
also
known
mpi
mita
eri
endoplasm
reticulum
er
ifn
stimul
critic
signal
molecul
innat
respons
cytosol
nucleicacid
ligand
furthermor
sting
recent
emerg
excit
target
immunolog
condit
ie
sting
inhibit
oncolog
ie
sting
activ
sting
role
immun
system
consist
higher
express
thymu
heart
spleen
placenta
lung
peripher
leukocyt
induct
type
ifn
major
outcom
sting
activ
vertebr
recent
becom
clear
sting
evolv
million
year
ago
predat
evolut
type
ifn
except
induct
type
ifn
sever
studi
unravel
induct
autophagi
process
primordi
function
cgasst
pathway
addit
cga
sting
subject
extens
regul
posttransl
modif
interact
protein
metal
ion
indic
import
precis
regul
pathway
bright
prospect
target
sting
regul
immun
respons
obvious
appeal
recent
clinic
achiev
garner
much
attent
scientif
commun
attract
drug
target
sting
subject
extens
structur
function
studi
identif
character
specif
modul
review
summar
recent
advanc
progress
studi
sting
pathway
structur
biolog
function
sting
sting
relat
diseas
well
rational
progress
develop
sting
modul
human
cga
identifi
broadspecif
cytosol
dna
sensor
atyp
among
innat
immun
sensor
receptor
biosynthet
enzym
cga
bind
dsdna
phosphat
backbon
therefor
make
bind
nonsequ
depend
activ
site
cga
rearrang
becom
compet
convert
adenosin
triphosph
atp
guanosin
triphosph
gtp
cyclic
guanosin
monophosphateeadenosin
monophosph
cgamp
produc
endogen
cgamp
ligand
turn
activ
sting
er
membran
fig
abil
singl
molecul
cga
produc
multipl
molecul
cgamp
provid
mechan
detect
small
amount
cytosol
dsdna
produc
rapidli
amplifi
antivir
signal
respons
besid
cgampmedi
activ
sting
activ
directli
bacteriaderiv
cyclic
dinucleotid
cdn
thu
cdn
endogen
pathogenderiv
potent
activ
sting
pathway
function
ubiquit
second
messeng
prokaryot
speci
eukaryot
upon
cgamp
bind
sting
transloc
er
golgi
via
ergolgi
intermedi
compart
ergic
tankbind
kinas
turn
phosphoryl
sting
lead
recruit
transcript
factor
interferon
regulatori
factor
phosphoryl
stingdepend
manner
result
dimer
transloc
nucleu
mediat
transcript
ifnb
coregul
gene
addit
direct
cytotox
effect
cancer
cell
ifnb
also
promot
matur
antigen
present
dendrit
cell
therebi
link
innat
immun
respons
adapt
immun
respons
meanwhil
bind
ifnb
receptor
activ
janu
kinas
jak
includ
tyrosin
kinas
turn
phosphoryl
receptor
process
allow
bind
dnabind
protein
signal
transduc
activ
transcript
receptor
whereupon
becom
phosphoryl
dimer
dimer
transloc
nucleu
upregul
transcript
interferonrespons
gene
includ
interferon
regulatori
factor
edepend
transcript
type
ifn
synthesi
releas
ifn
bind
interferon
receptor
upregul
sting
transcript
proinflammatori
cytokin
gene
posit
feedback
loop
cgasst
signal
cascad
also
function
across
neighbor
cell
via
gapjunct
commun
may
connect
distant
cell
type
tissu
packag
cgamp
viral
particl
fig
given
selfdna
trigger
stingmedi
respons
pathway
requir
precis
control
avoid
excess
immun
respons
fig
protein
homolog
member
lsm
smlike
protein
famili
involv
rna
process
process
bodi
play
import
role
maintain
matur
mrna
level
sting
cell
typeespecif
manner
meanwhil
activ
traffick
sting
phosphoryl
serinethreonineprotein
kinas
protein
trigger
cgasgener
cdn
order
suppress
activ
therefor
cdn
may
also
initi
negativefeedback
control
mechan
thwart
prolong
innat
immun
gene
transcript
prevent
inflammatori
disord
autophagyrel
protein
restrict
sting
transloc
golgi
apparatu
regul
assembl
sting
nodlik
receptor
associ
sting
prevent
traffick
er
golgi
result
reduc
respons
type
ifn
zinc
finger
dhhc
domaincontain
protein
member
aspartatehistidinehistidinecystein
palmitoyl
acyltransferas
famili
associ
sting
er
golgi
apparatu
viral
dna
stimul
posit
modul
sting
activ
lead
increas
engag
type
ifn
product
ubx
domaincontain
protein
complex
sting
ubiquitinprotein
ligas
posit
regul
stingdepend
innat
immun
respons
sting
also
shown
neg
regul
ubiquitin
transferas
ring
finger
protein
mediat
ubiquitin
lead
sting
degrad
interestingli
ring
finger
protein
shown
attenu
sting
ubiquitin
without
affect
sting
ubiquitin
suggest
posit
regul
sting
signal
mechan
remain
clarifi
regul
coordin
host
cell
make
cgasst
pathway
function
wellbalanc
system
recent
mount
evid
reveal
cgasest
pathway
activ
autophagi
robustli
ancient
highli
conserv
function
predat
evolut
type
ifn
fig
note
cgampinduc
autophagi
clear
cytosol
virus
dna
effect
indic
crucial
role
antivir
defenc
ergic
contain
cgampbound
sting
serv
membran
sourc
recruit
lipid
process
wd
repeat
domain
phosphoinositideinteract
protein
depend
mechan
import
lipid
convent
autophagi
pathway
membran
target
dna
pathogen
autophagosom
subsequ
fuse
lysosom
process
requir
rasrel
protein
gtpase
molecular
understand
key
step
underli
cgasst
pathway
recent
set
howev
mechan
everi
step
less
clear
controversi
case
exampl
question
cgamp
activ
sting
activ
sting
trigger
recruit
activ
remain
character
notabl
structur
sting
repres
uniqu
fold
structur
homolog
known
protein
undoubtedli
sting
mysteri
promis
drug
target
sting
transmembran
protein
consist
ntermin
transmembran
domain
contain
four
transmembran
helic
globular
ctermin
domain
ctd
includ
dimer
domain
predict
local
cytosol
fig
base
biophys
xray
crystallograph
data
sting
ctd
exist
butterflyshap
dimer
ligand
bind
site
locat
dimer
interfac
cgamp
act
glue
reinforc
sting
homodim
induc
conform
chang
sting
open
close
fig
two
monom
sting
shift
slightli
rel
clamp
onto
ligand
bind
site
wherea
bsheet
lid
region
fig
seal
larg
bind
pocket
nm
fig
thu
form
close
conform
ctd
activ
sting
undergo
extens
conform
alter
trigger
sting
transloc
er
golgi
traffick
golgi
sting
palmitoyl
transmembran
domain
golgi
fig
b
palmitoyl
may
promot
sting
oligomer
subsequ
activ
howev
recruit
ca
nt
activ
alon
differ
protein
kinas
whose
activ
synonym
phosphoryl
substrat
rather
phosphoryl
conserv
consensu
plxi
p
hydrophil
residu
x
residu
motif
present
ctermin
tail
sting
requir
sting
licens
interact
fig
e
subsequ
phosphoryl
dimer
transloc
nucleu
drive
type
ifn
express
initi
downstream
signal
sting
degrad
endolysosom
motif
amino
acid
requir
traffick
mediat
sting
degrad
fig
play
crucial
role
cgamp
induc
autophagi
phosphoryl
fig
although
human
sting
protein
activ
cdn
robustli
certain
singl
nucleotid
polymorph
snp
within
transmembran
protein
dwhich
encod
stingdcan
differenti
sensit
sting
cdn
analysi
snp
data
genom
project
reveal
sting
haq
occur
sting
aq
human
fig
cgasst
pathway
cytosol
dna
sens
cytosol
dna
bind
activ
cga
catalyz
synthesi
atp
gtp
bind
er
adaptor
sting
traffic
ergolgi
intermedi
compart
ergic
golgi
apparatu
tansmembran
domain
sting
palmitoyl
palmitoyl
sting
cluster
produc
oligmer
recruit
phosphoryl
sting
turn
recruit
phosphoryl
phosphoryl
dimer
enter
nucleu
function
nfkb
turn
express
type
interferon
immunomodulatori
molecul
furthermor
ergic
contain
cgampbound
sting
serv
membran
sourc
recruit
lipid
mechan
membran
target
dna
pathogen
autophagosom
subsequ
fuse
lysosom
process
requir
gtpase
popul
human
sting
harbour
activ
bacteri
cdn
well
endogen
cgamp
wherea
sting
variant
histidin
posit
poorli
respons
bacteri
cdn
effect
activ
endogen
cgamp
dramat
decreas
sensit
bacteri
cdn
ligand
howev
sting
aq
sting
haq
variant
maintain
partial
abil
activ
ifnb
signal
presenc
ligand
due
primarili
substitut
right
chicken
sting
cgamp
close
conform
pdb
code
cy
cy
transmembran
domain
palmitoyl
may
promot
sting
oligomer
subsequ
activ
color
green
yellow
respect
appear
lid
region
featur
close
conform
c
globular
ctermin
domain
human
sting
larg
bind
pocket
pdb
code
densiti
two
protom
dimer
color
gray
blue
densiti
two
sting
ctermin
tail
color
yellow
pdb
code
e
phosphoryl
sting
ctermin
tail
complex
color
blue
yellow
respect
residu
magenta
sting
ctermin
tail
requir
sting
licens
interact
pdb
interpret
refer
color
figur
legend
reader
refer
web
version
articl
biochem
analysi
reveal
conform
lid
region
sting
significantli
alter
compar
wild
type
sting
mice
sting
variant
also
defect
type
ifn
induct
respons
cdn
interestingli
altern
snp
report
result
gainoffunct
phenotyp
hyperactiv
condit
without
cdn
stimul
accordingli
like
contribut
sever
inflammatori
disord
introduc
follow
chapter
taken
togeth
complet
understand
snp
within
may
predict
suscept
pathogen
infect
perhap
respons
immun
regim
sting
function
extens
studi
viral
infect
due
major
role
induct
type
ifn
review
recent
studi
differ
virus
shown
viral
genom
releas
cytosol
upon
infect
trigger
stingdepend
signal
cascad
retroviru
replic
lead
accumul
sever
dna
contain
nucleic
acid
structur
capac
stimul
cgasst
axi
retrovir
dna
retrovir
rna
dna
hybrid
singlestrand
dna
ssdna
speci
final
dsdna
intriguingli
studi
demonstr
virusinduc
cellular
stress
virusfus
also
trigger
cgasst
pathway
independ
viral
nucleic
acid
suggest
complex
role
sting
possibl
interact
complex
govern
membran
dynam
howev
remain
unresolv
whether
sting
genuin
signal
molecul
govern
membranereorgan
process
suppos
essenti
certain
virusdetect
pathway
constant
arm
race
pathogen
host
microb
evolv
divers
way
evad
attack
immun
respons
suscept
host
microb
common
effect
way
avoid
trigger
cgasst
pathway
hide
dna
cytoplasm
retrovirus
mani
dna
virus
keep
dna
viral
capsid
travers
cytoplasm
deliv
viral
dna
nucleu
asid
dna
recognit
infect
cell
upstream
downstream
cgasst
pathway
damag
brake
antivir
signal
cascad
kaposi
sarcomaassoci
herpesviru
kshv
cope
cgasst
pathway
variou
mechan
includ
disrupt
dna
bind
upstream
dna
sensor
sting
interferong
induc
protein
cga
dismiss
sting
bind
inhibit
sting
phosphoryl
herpesvirus
hsv
hydrolyz
polyubiquitin
chain
sting
prevent
ubiquitin
neg
regul
stingmedi
signal
similarli
coronavirus
porcin
epidem
diarrhea
viru
pedv
reduc
ubiquitin
statu
sting
influenza
viru
interact
sting
conserv
hemagglutinin
fusion
peptid
fp
inhibit
sting
activ
respons
membran
fusion
recent
proteas
sever
flavivirus
shown
cleav
sting
sequenc
lrrg
ntermin
domain
furthermor
dengu
viru
target
cga
induc
degrad
prevent
mitochondri
dna
sens
infect
gramneg
gramposit
bacteria
also
report
promot
sting
signal
includ
legionella
pneumophila
francisella
tularensi
chlamydia
muridarum
streptococcu
pyogen
brucella
abortu
mycobacterium
tuberculosi
overal
bacteri
dna
recognit
cga
seem
main
stimulu
type
ifn
induct
effect
bacteri
cdn
sting
updat
knowledg
relationship
microorgan
host
bacteri
cdn
ca
nt
induc
interferon
absenc
cga
except
listeria
monocytogen
induc
interferon
stingdepend
manner
cga
one
possibl
bacteri
host
cell
contain
enzym
select
digest
bacteri
cdn
endogen
cgamp
produc
host
cell
exampl
agalactia
degrad
cdn
present
outsid
bacteria
via
cellwal
anchor
ectonucleotidas
major
subset
patient
advanc
solid
tumor
show
spontan
cell
inflam
tumor
microenviron
tme
prognost
import
associ
clinic
respons
immunotherapi
anoth
major
subset
dose
clue
glean
human
cancer
gene
express
profil
studi
reveal
associ
type
ifn
signatur
cellinflam
tme
clinic
outcom
accumul
evid
suggest
type
ifn
product
might
integr
involv
adapt
cell
respons
tumor
antigen
allow
focu
innat
immun
sens
pathway
known
trigger
type
ifn
product
necessari
optim
cell
prime
tumor
antigen
import
strategi
trigger
innat
signal
via
antigenpres
cell
apc
tme
might
facilit
better
crossprim
tumor
antigenspecif
cell
augment
chemokin
product
subsequ
effector
cell
traffick
cellinflam
tme
play
crucial
role
tumor
regress
thu
yield
improv
clinic
outcom
defin
innat
immun
mechan
involv
cancer
immunotherapi
includ
limit
antitumor
immun
respons
elicit
recognit
tumorderiv
antigen
tolllik
receptor
tlr
retino
acidinduc
genei
rigi
like
receptor
rlr
well
sensat
tumorderiv
dna
sting
dna
deriv
die
tumor
cell
enter
cytosol
dendrit
cell
consequ
ligat
phagocytosi
cellecel
contact
lead
induct
sting
signal
meanwhil
rigi
stimul
coupl
potenti
respons
sting
could
impact
adapt
immun
respons
cancer
immunotherapi
therefor
insight
mechan
tlr
rlr
stingmedi
innat
immun
signal
cancer
immun
evas
tumorigenesi
cancer
develop
may
lead
discoveri
novel
therapeut
target
cancer
therapi
recent
cgasst
signal
shown
import
respons
radiat
therapi
immun
checkpoint
blockad
radiat
prompt
dna
damag
host
cell
elicit
strong
inflammatori
trigger
dangerassoci
molecular
pattern
damp
dna
damag
lead
nucleosom
leakag
cytosol
selfdna
trigger
stingdepend
cytokin
product
tumor
antigenspecif
cell
effect
control
growth
cancer
cell
vivo
must
gain
access
function
within
tme
thu
convert
uninflam
cold
tumor
nt
respond
checkpoint
inhibitor
respons
hot
cancer
accordingli
sting
pathway
project
essenti
pathway
target
cancer
therapi
stimul
adapt
immun
respons
system
provid
longliv
immunolog
memori
mani
studi
discov
cdn
treatment
increas
tumor
immun
cell
express
combin
sting
agonist
mab
potenti
translat
clinic
especi
checkpoint
blockad
resist
case
interestingli
cancer
cell
exhibit
altern
signal
outcom
respons
small
molecular
sting
agonist
manifest
apoptosi
rather
product
type
ifn
sharp
contrast
respons
elicit
sting
agonist
macrophag
dendrit
cell
mous
embryon
fibroblast
mef
found
larg
apoptosisresist
promis
stingmedi
stimul
apoptosi
explor
treatment
option
context
tcellderiv
human
malign
howev
activ
cgasest
pathway
also
lead
tolerogen
respons
induct
indolamin
ido
activ
sting
promot
growth
tumor
low
antigen
higher
antigen
brainmetastat
cancer
cell
produc
cgamp
transfer
neighbor
astrocyt
activ
product
inflammatori
cytokin
facilit
metastasi
consequ
studi
warrant
caution
ongo
clinic
effort
enhanc
cancer
immunotherapi
stimul
sting
pathway
cgamp
analog
collect
good
clinic
outcom
probabl
achiev
optim
combin
differ
treatment
includ
stimul
innat
immun
system
blockad
immun
checkpoint
radiat
target
cytotox
agent
even
adopt
cell
transfer
inflamm
almost
caus
lead
releas
cellular
debri
includ
dna
rna
wherea
extracellular
nucleas
help
degrad
dna
fairli
abund
selfnucl
acid
still
enter
innat
immun
cell
multipl
mechan
although
subtl
biochem
modif
contain
within
host
bacteri
nucleic
acid
may
alter
sens
human
phagocyt
mani
case
sensor
respond
equal
nucleic
acid
regardless
origin
task
selfenonself
discrimin
particularli
challeng
innat
immun
cell
increas
evid
suggest
misloc
nuclear
mitochondri
dsdna
cytoplasm
combin
inabl
cga
differenti
foreign
self
dsdna
crucial
pathogenesi
autoinflamm
type
ifn
misloc
dsdna
hallmark
key
driver
pathogenesi
autoimmun
diseas
system
lupu
erythematosu
sle
addit
loss
function
mutat
dna
exonucleas
threeprim
repair
exonucleas
ensur
apoptot
cell
remain
immunolog
silent
follow
phagocytosi
lead
excess
type
ifn
signatur
found
syndrom
ag
sle
implic
role
selfdsdna
autoinflamm
furthermor
monogen
mendelian
diseas
sting
gain
function
mutat
famili
chilblain
lupu
fcl
support
role
sting
autoimmun
diseas
studi
collect
suggest
cgasst
pathway
might
regul
dnadriven
inflammatori
diseas
mutat
caus
sting
activ
failur
elimin
selfdna
leak
cytosol
mutat
sting
lead
constitut
activ
caus
autoinflammatori
diseas
stingassoci
vasculopathi
onset
infanc
savi
patient
fcl
sting
harbour
mutat
induc
new
intramolecular
polar
interact
make
structur
sting
dimer
tighter
result
constitut
type
ifn
signal
absenc
cgamp
ligand
similarli
patient
vascular
pulmonari
syndrom
vap
found
exhibit
three
mutat
exon
variant
potent
stimul
type
ifn
promot
determin
vitro
express
studi
cell
specul
mutat
may
expedit
sting
traffick
endoplasm
reticulum
perinuclear
region
affect
sting
protein
stabil
therebi
sustain
sting
activ
hiroyasu
konno
et
al
identifi
sting
new
gainoffunct
mutat
requir
cdn
augment
activ
taken
togeth
gainoffunct
mutat
screen
monogen
caus
broad
spectrum
diseas
sting
could
repres
new
therapeut
target
disord
well
common
inflammatori
diseas
trigger
cytosol
dna
stimul
microbi
endogen
origin
pharmacolog
activ
stingdepend
signal
shown
promis
divers
clinic
impact
applic
includ
broadact
antivir
treatment
vaccin
adjuv
immunogen
tumor
clearanc
led
academ
commerci
effort
formul
cdn
pharmaceut
use
includ
advanc
ongo
clinic
trial
unfortun
cdn
may
chemic
undesir
research
clinic
work
sinc
violat
lipinski
rule
druglik
amen
larg
structur
chang
suscept
phosphodiesterasemedi
degrad
size
hydrophil
render
imperm
cell
membran
small
molecular
sting
activ
mitig
factor
wellexemplifi
mousespecif
compound
acid
dmxaa
identif
novel
small
molecul
sting
agonist
efficaci
across
speci
thu
highli
sought
sinc
may
develop
valuabl
research
tool
understand
stingmedi
process
furthermor
use
anim
enabl
broad
assess
safeti
biolog
mechan
cdn
first
describ
bacteria
known
natur
occur
exampl
consist
two
nucleotid
g
cycliz
canon
phosphodiest
bond
form
cyclicdigmp
cdigmp
cyclicdiamp
cdiamp
cgamp
fig
endogen
cdn
produc
cga
known
mammalian
cdn
name
cgamp
fig
chemic
distinct
bacteri
cdn
cgamp
fig
contain
mix
phosphodiest
bond
interestingli
rel
cgamp
cdn
cgamp
show
exquisit
high
affin
sting
elicit
stronger
type
ifn
respons
k
cgamp
lower
cdigmp
cgamp
cgamp
lower
cgamp
meanwhil
given
free
cdn
alon
permeat
cell
membran
ineffici
vitro
requir
addit
lipofectamin
anoth
transfect
reagent
differ
transmembran
capabl
variou
cdn
affect
function
type
ifn
extent
accord
structur
studi
cgamp
adopt
order
conform
free
ligand
form
moreextens
interact
insid
sting
ligandbind
pocket
compar
cgamp
therebi
stabil
specif
intermedi
state
readili
cover
lid
fig
smallmolecul
natur
cgamp
promis
sting
spur
interest
appli
sting
agonist
vaccin
adjuv
immunotherapi
given
cdn
poor
druglik
technolog
deliv
cdn
cytosol
requir
intraven
inject
cdigmp
encapsul
within
induc
strike
decreas
metastat
lesion
mous
melanoma
model
almost
mice
show
full
protect
tumor
rechalleng
suggest
induct
memori
adapt
immun
respons
biopolym
implant
also
use
codeliv
cdigmp
chimer
antigen
receptor
cart
cell
meanwhil
stingactiv
nanoparticl
stingnp
dration
design
polymersom
enhanc
cytosol
deliveri
cgamp
enhanc
sting
signal
tme
sentinel
lymph
node
convert
immunosuppress
tumor
immunogen
tumoricid
microenviron
recent
combin
cytotox
cation
silica
nanoparticl
cdigmp
show
dramat
increas
expans
antigenspecif
cell
potent
tumor
growth
inhibit
murin
melanoma
taken
togeth
cdn
high
translat
potenti
therapeut
intervent
strategi
induc
activ
tme
multipl
tumor
type
mechanist
goal
gener
effect
tumoriniti
cell
prime
last
antitumor
efficaci
synthet
cdn
favor
properti
urgent
need
newli
design
compound
enter
trial
patient
advanc
metastat
solid
tumor
lymphoma
fig
increas
enzymat
stabil
sulfur
use
replac
nonbridg
oxygen
phosphodiest
linkag
make
phosphorothio
result
compound
cgsasmp
fig
resist
degrad
ectonucleotid
pyrophosphatas
identifi
major
cgamp
hydrolas
prolong
system
halflif
maintain
high
affin
sting
anoth
dithio
cdn
analog
made
two
amp
moieti
cycliz
via
bond
known
fig
show
improv
ifnb
respons
tumor
regress
establish
tumor
compar
cgamp
antitumor
efficaci
also
observ
intratumor
inject
mous
model
substanti
system
immun
respons
capabl
reject
distant
metastas
provid
longliv
immunolog
memori
strike
preclin
result
provid
support
use
clinic
trial
patient
advanc
metastat
solid
tumor
lymphoma
clinicaltrialsgov
first
result
expect
merck
co
launch
trial
earli
cdn
compound
alon
combin
approv
checkpoint
blocker
pembrolizumab
clinicaltrialsgov
structur
molecul
yet
disclos
bristolmy
squibb
bm
acquir
biotech
ifm
therapeut
put
us
million
upfront
get
hand
preclin
cdn
agonist
fig
mucos
administr
sting
agonist
caimp
fig
evok
local
ifn
respons
confer
total
protect
genit
herp
even
highli
permiss
mous
strain
gener
efficaci
cdn
limit
drug
deliveri
barrier
includ
poor
cellular
target
rapid
clearanc
ineffici
transport
cytosol
sting
local
even
nucleotid
anion
natur
warrant
develop
molecul
improv
druglik
qualiti
simpl
chemic
synthesi
favor
pharmacokinet
profil
differ
cdn
activ
sting
univers
dmxaa
also
known
vadimezan
fig
first
small
molecul
discov
potent
agonist
mous
sting
msting
regrett
human
sting
hsting
may
explain
failur
dmxaa
clinic
trial
human
cancer
cma
fig
dmxaa
structur
similar
like
dmxaa
cma
also
show
impress
anticanc
activ
mice
fail
men
accord
structur
research
sting
modif
dmxaa
like
produc
potent
modul
hsting
atomiclevel
understand
interact
dmxaa
hsting
becam
avail
eleg
structur
biophys
cellular
assay
studi
report
gao
pu
cowork
identifi
three
point
substitut
hsting
synergist
render
mutat
hsting
highli
sensit
dmxaa
fig
inspir
structur
function
result
shed
light
strategi
restor
effici
hsting
respons
dmxaa
base
bindingpocket
substitut
xing
che
et
al
discov
mutat
togeth
endow
human
sting
aq
dmxaa
sensit
molecular
dynam
simul
show
two
mutat
chang
interact
network
dmxaa
sting
aq
moreov
smaller
number
water
molecul
displac
upon
dmxaa
bind
sting
aq
bind
mutant
lead
larger
entrop
penalti
former
ami
shih
et
al
unravel
dynam
structur
differ
hsting
msting
simul
found
side
chain
correspond
residu
hsting
g
enough
form
steric
barrier
prevent
exit
dmxaa
wherea
wildtyp
hsting
without
side
chain
form
porou
lid
region
allow
dmxaa
exit
observ
gave
us
insight
translat
sting
agonist
mous
activ
human
activ
also
provid
avenu
pursu
design
smallmolecul
drug
target
human
sting
current
effort
gener
reciproc
dmxaa
deriv
contain
polar
group
oh
f
cl
substitut
substitut
posit
within
dmxaa
ring
form
addit
intermolecular
hydrogen
bond
well
replac
sixmemb
aromat
ring
fivememb
counterpart
given
two
molecul
dmxaa
bind
sting
dimer
ongo
effort
also
direct
toward
gener
evalu
coval
link
dmxaa
dimer
meanwhil
involv
redistribut
substitut
dmxaa
scaffold
identifi
weak
yet
humanact
possibl
also
humanselect
dmxaa
analog
meanwhil
yibo
zhang
et
al
identifi
amangostin
fig
share
xanthon
skeleton
dmxaa
weak
agonist
hsting
find
provid
critic
guid
futur
ration
drug
design
dmxaa
variant
potenti
enhanc
interferon
product
human
need
develop
anticanc
therapi
vaccin
adjuv
direct
sting
agonist
use
wide
preclin
clinic
studi
treatment
cancer
sting
agonist
modifi
cdn
limit
clinic
applic
due
poor
druggabl
howev
huge
challeng
develop
small
molecular
sting
agonist
humanact
suitabl
system
administr
larg
bind
pocket
sting
post
challeng
drug
design
demand
da
molecular
weight
ligand
gener
possess
undesir
physicochem
properti
bryan
gall
et
al
conduct
highthroughput
screen
assay
identifi
n
methylcarbamoyl
phenylacetamid
refer
fig
novel
compound
trigger
respons
stingdepend
manner
luciferas
activ
thf
report
cell
line
increas
mock
treatment
mm
similarli
tina
sali
et
al
identifi
n
b
refer
fig
select
induc
stingdepend
synthesi
secret
bioactiv
interferon
bowei
liu
et
al
identifi
dispiro
diketopiperzin
dsdp
fig
induc
proinflammatori
cytokin
respons
manner
depend
express
function
hsting
select
cc
valu
dsdp
greater
mm
correspond
report
cell
line
howev
small
agonist
lack
evid
suggest
compound
bind
directli
sting
excitingli
joshi
ramanjulu
et
al
discov
new
class
synthet
small
molecular
sting
agonist
suitabl
system
administr
name
dimer
amidobenzimidazol
diabzi
similar
cgamp
fig
induc
dosedepend
secret
ifnb
appar
effect
constant
ec
app
mm
around
potent
cgamp
ec
app
mm
lead
optim
fig
select
induc
dosedepend
activ
sting
secret
ifnb
ec
app
nm
potent
cgamp
human
peripher
blood
mononuclear
cell
pbmc
differ
cgamp
induc
sting
close
conform
diabzi
activ
sting
open
conform
fig
intraven
administr
diabzi
immunocompet
mice
establish
syngen
colon
tumor
elicit
strong
antitumor
activ
complet
last
regress
tumor
abzi
seri
sting
agonist
bring
new
chemic
class
complet
differ
physicochem
properti
cdn
class
enrich
chemic
space
activ
sting
provid
option
clinic
develop
sting
agonist
biolog
rational
link
sting
inflammatori
diseas
support
develop
sting
antagonist
howev
gener
lack
biochem
mechanist
understand
sting
activ
lead
signific
challeng
develop
binder
sting
protein
inspir
possibl
util
bind
stochiometri
offset
challeng
larg
bind
pocket
thu
effect
compet
cgamp
still
maintain
physiochem
properti
compat
oral
drug
help
autom
ligand
identif
system
ali
toni
siu
identifi
weak
antagonist
fig
stingmedi
signal
compet
cgamp
bind
ratio
inact
open
conform
fig
compound
stimul
ifnb
product
ec
mm
modestli
inhibit
cgamp
induc
ifnb
product
ic
mm
shift
potenc
bind
function
cell
assay
consid
assay
stimul
nonphysiolog
level
cgamp
specul
cellular
ic
valu
may
accur
represent
antagonist
potenc
senlin
li
et
al
identifi
astin
c
fig
cyclopeptid
isol
medicin
plant
aster
tataricu
specif
block
recruit
onto
sting
signalosom
bind
sting
ctd
astin
c
show
compar
bind
affin
sting
cgamp
dissoci
constant
valu
k
nm
inhibitori
effect
astin
c
intracellular
dnainduc
ifnb
express
dose
depend
ic
valu
mm
mef
human
fetal
lung
fibroblast
cell
respect
larg
unknown
ntermin
region
four
predict
transmembran
helic
contribut
sting
function
recent
studi
identifi
ntermin
cystein
residu
posit
palmitoyl
site
palmitoyl
import
stingdepend
phosphoryl
transgolgi
network
thu
central
sting
depend
induct
type
ifn
ann
louis
hansen
et
al
report
endogen
nitroconjug
linol
acid
fig
coval
modifi
sting
nitroalkyl
lead
deregul
sting
palmitoyl
inhibit
sting
signal
human
cell
like
fibroblast
savi
patient
sinc
report
welltoler
treatment
human
clinicaltrialsgov
find
consider
medic
potenti
simon
haag
et
al
perform
cellbas
chemic
screen
identifi
two
nitrofuran
fig
fig
dthat
strongli
inhibit
msting
select
coval
target
prevent
palmitoyl
prevent
sting
interact
furthermor
found
fig
could
effici
inhibit
hsting
select
mechan
meanwhil
signific
vivo
studi
provid
proofofconcept
sting
antagonist
efficaci
treatment
autoinflammatori
diseas
initi
success
therapi
target
immunostimulatori
effect
cgasst
pathway
suggest
major
clinic
impact
area
cancer
immunotherapi
vaccin
develop
autoimmun
diseas
howev
challeng
design
small
molecul
dimer
interfac
sting
ctd
domin
hydrophob
interact
salt
bridg
particip
dimer
hydrophob
interfac
may
lead
discoveri
fals
posit
hit
furthermor
larg
ligand
bind
pocket
sting
requir
ligand
da
occupi
inevit
ligand
larg
volum
may
caus
downstream
develop
problem
toxic
poor
pharmacokinet
joshi
ramanjulu
et
al
design
linker
two
amidobenzimidazol
molecul
enhanc
activ
significantli
similarli
toni
siu
et
al
inspir
dmxaa
bind
sting
ratio
identifi
seri
antagonist
conclud
maxim
buri
interact
sting
protein
achiev
maintain
ligand
physicochem
properti
necessari
oral
exposur
mainstream
open
close
conform
chang
charg
sting
activ
howev
two
seri
compound
bind
sting
ctd
open
conform
produc
opposit
effect
undoubtedli
inform
crystal
structur
insuffici
differ
ligandprotein
interact
may
capac
alter
protein
flexibl
dynam
ultim
function
recogn
dynam
import
popul
avail
protein
conform
state
rate
probabl
state
redistribut
upon
ligand
bind
protein
shift
conform
popul
cooper
motion
enabl
function
consequ
urgent
need
molecular
dynam
studi
sting
taken
togeth
crystal
structur
sting
avail
advanc
molecular
dynam
studi
structurebas
andor
ligandbas
design
may
util
design
novel
small
molecular
modul
target
sting
improv
selectivityspecif
profil
except
molecul
bind
sting
directli
pharmacolog
intervent
aim
modul
upstream
downstream
signal
may
hold
similar
promis
exampl
mavupharma
compani
identifi
firstinclass
oral
activ
small
molecul
inhibitor
phosphodiesteras
hydrolysi
cgamp
select
inhibit
activ
allow
highlycontrol
enhanc
sting
signal
tumor
lymph
node
without
inject
molecul
aim
antagon
cga
sting
function
hold
similar
promis
instanc
suramin
found
highaffin
inhibitor
cga
interestingli
antimalari
drug
includ
quinacrin
chloroquin
also
report
dismiss
activ
cga
moreov
disrupt
degrad
express
sting
may
provid
new
insight
develop
small
molecular
modul
sting
activ
consid
complic
mechan
regul
magnitud
cgasst
pathway
signal
remain
clarifi
choos
sting
drug
target
consciou
potenti
risk
henriqu
lemo
et
al
identifi
sting
agonist
could
promot
growth
tumor
character
low
antigen
via
activ
ido
immun
checkpoint
attenu
tumor
immun
consequ
sting
agonist
may
effect
tumor
set
particularli
robust
tolerogen
respons
dna
low
tumor
antigen
prevail
furthermor
hyperactiv
sting
like
spark
sever
inflammatori
respons
call
cytokin
storm
level
cytokin
becom
abnorm
high
occurr
cytokin
storm
result
fever
low
blood
pressur
heart
problem
case
organ
failur
death
meanwhil
exist
snp
hsting
lead
patient
show
low
respons
sting
agonist
combin
person
cancer
immunotherapi
offer
potenti
make
therapi
specif
effect
safer
compar
cancer
immunotherapi
avail
today
clear
stand
import
crossroad
opportun
enhanc
abil
use
immun
system
make
cancer
control
case
curabl
diseas
indepth
understand
cgasst
pathway
includ
care
consider
possibl
speciesspecif
differ
instrument
develop
therapeut
target
dnasens
pathway
success
pharmacolog
agonist
antagonist
cga
sting
could
becom
effect
therapi
mani
preval
emerg
diseas
includ
infecti
autoimmun
inflammatori
cancer
end
one
remind
honey
never
far
away
sting
